|
|
News Breaks | | | | December 10, 2012 | | 18:22 EDT |  | INCY | Incyte's Jakafi trials suggest survival benefits for patients with myelofibrosis
Incyte Corporation announced that several analyses from clinical studies of Jakafi were presented at the 2012 American Society of Hematology Annual Meeting. Jakafi, an oral Janus kinase, or JAK, inhibitor, is FDA-approved for the treatment of patients with intermediate or high-risk myelofibrosis, or MF. In long-term results from two randomized Phase III clinical trials -- COMFORT-I and COMFORT-II -- patients with myelofibrosis treated with Jakafi had improved survival over placebo and best available therapy, suggesting an overall survival benefit. Additionally, data from an ongoing Phase II trial suggest that long-term treatment with Jakafi may be a durably efficacious therapy for patients with polycythemia vera. | |
|
News For INCY From The Last 14 Days Check below for free stories on INCY the last two weeks. |
|
|
| May 7, 2013 | | 06:23 EDT |  | INCY | Incyte coverage resumed with a Sell at Goldman
Target $17. | |
|
|
|
|
|
|
